% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • levonchiko levonchiko May 22, 2013 6:26 PM Flag


    We believe that ARKACE will meet the phase III trial's primary endpoint of non inferiority to TOBI in change from baseline in FEV1 and could potentially show superiority.Positive results from the trial will support an NDA submission in the EU and US in late 2013/early 2014. we see upside to $18 price target should ARIKACE be shown to be numerically and/or statistically superior to TOBI,as we believe this data would further set the product apart in CF market place.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
11.06-0.11(-0.98%)Jul 22 4:00 PMEDT